Latest! Global pharmaceutical and equipment enterprises TOP15 employee per capita performance ranking

Enterprise "per capita efficiency" (including per capita output value, per capita profit) is a more important operational indicator; Especially in the big health industry, under the background of the gradual replacement of "man-sea tactics" by "elite military strategy", enterprises are paying more and more attention to "human effectiveness" indicators

With the release of the financial reports of major enterprises in the first half of 2022, medical talents have counted the revenue list of top 15 enterprises in the big health industry (pharmaceuticals, devices, IVDs); In addition, for the first time, a very important indicator of "effectiveness per capita" was ranked

In the first half of 2022, what is the ranking of the top 15 global health industry revenue and per capita efficiency?

2022H1 Global Pharmaceutical and Device Enterprises TOP15 Revenue List:

Pfizer, Johnson & Johnson, Roche top three

Looking at the entire big health industry (pharmaceuticals, medical devices, IVDs), the pharmaceutical field is in the upstream regardless of revenue amount and growth rate; And U.

Takeda Pharmaceutical's first half of fiscal 2022 is (April 2022 to September 2022), which is not included in the top 15 global pharmaceutical and device companies in the first half of 2022

In the TOP15, the group (pharmaceutical, medical device) listed 3 companies, including: Johnson & Johnson, Roche, Abbott; 11 pharmaceutical companies on the list, including: Pfizer, Merck, AbbVie, Novartis, Bristol-Myers Squibb, AstraZeneca, Sanofi, GlaxoSmithKline, Eli Lilly, Gilead, Amgen; 1 medical device listed company, Medtronic;

Among them: 11 American companies, two British companies, and one Swiss and French enterprises

Per capita effectiveness is an important measure for companies with different life cycles

2022H1 Global Pharmaceutical and Equipment Enterprises TOP15 Per Capita Performance List:

Gilead, BMS, Pfizer top three

Usually, the number of enterprise revenue/personnel is called "personnel effectiveness" (this list is the top 15 pharmaceutical and equipment enterprises in terms of revenue

Novartis and Sanofi's 2022 layoffs are underway

In the first half of 2022, the top three "per capita effectiveness" of employees in TOP15 pharmaceutical and device companies were: Gilead, Bristol-Myers Squibb, and Pfizer

Bristol-Myers Squibb: Revenue of $23.

Pfizer: Revenue of $53.

After deducting operating costs, R&D sales costs, other expenses, taxes and other expenses, from the perspective of (net output value per capita), the top three are: Pfizer (US$225,000), Merck (US$121,000), Amgen (US$115,000).

The top five companies in terms of per capita performance (Gilead, BMS, Pfizer, AbbVie, Amgen) all have less than 80,000 employees;

The top five companies in terms of per capita effectiveness (Novartis, Sanofi, Abbott, GSK, Medtronic) have 100,000 or more

In 2022, the big health industry has entered the stage

In order to improve per capita efficiency, novartis and Sanofi, the bottom five, also focused on efficiency through a series of strategic adjustments, including splitting, merging, and reducing staff.

May:

Novartis, announcing that it expects to lay off about 8,000 jobs worldwide to save $1 billion; This is mainly due to major architectural changes
that began in April.
In August, it first laid off employees from its headquarters in Switzerland, and is expected to involve 1,400 positions, more than half of which are managers
.

April:

Sanofi, after the completion of the previous acquisition of Kadmon, some businesses will be permanently closed after the integration of resources; The layoffs are expected to begin on July 1 and end
on April 1, 2023.
In addition, at the 2022Q1 Investor Conference, Sanofi's CFO said it plans to reduce employees to below 90,000 by the end of this year and expects to lay off about 6,000 employees
in 2022.

Sustainable growth in the health industry, mainly from heavy pipelines and innovation; High-quality best-selling products are an important basis for
these companies to lead in performance per capita.

2022H1 Big Health Human Effect TOP15 Pipeline

As can be seen above, bio-innovative drugs are indeed a "high-return" industry, and the revenue of a best-selling drug is even higher than that of the entire department of
medical device companies.
In addition to the high revenue of new crown vaccines and drugs under the special background of the epidemic, most of the pipelines leading growth focus on biological innovative drugs
in the field of tumors and autoimmunity.

Pfizer's COVID-19 products totaled $31.
7 billion, accounting for 59% of its total revenue; In addition to this, the highest sales volume was only $
3.
537 billion for the coagulant Eliquis, which had been on the market for many years.
To this end, Pfizer, which holds a huge amount of cash, is actively laying out the future product matrix, and has spent $17.
5 billion on acquisitions
since 2022 alone.

Johnson & Johnson's TOP1 product, the self-drug Stelara (usinorumab), ranked 8th among the world's best-selling drugs with nearly $5 billion in revenue
.

Roche has been surpassed by Bristol-Myers Squibb (acquisition of Xinji) in the field of tumor segmentation, ranking second in the world; Its three best-selling drugs, Ocrevus (self-explanatory), Perjeta (tumor), and Hemlibra (hemophilia), have been called the "new troika", and the areas covered are no longer focused on tumors
.

The battle between Aber Repair Merlot ($10.
099 billion) and Merck K ($10.
061 billion) may be the highlight of the pharmaceutical sector this year and in the coming years, with only $38 million in
revenue in the first half of the year.

In addition to continuing to play the advantages of Humira, AbbVie's new products in the field of immunity and oncology are also optimistic
.
For example, the JAK inhibitors Rinvoq and Skyrizi, which have been on the market for less than two years, have been approved for multiple indications, with sales of more than $3.
2 billion in the first half of 2022, and AbbVie expects these two drugs to bring $15 billion in revenue
by 2025.

According to the ROE of return on net assets, the top three are: AbbVie, Eli Lilly, Amgen, the higher the indicator value, indicating that the higher the return brought by shareholder investment, or will attract more capital
.

For enterprises, "per capita efficiency" is the embodiment of enterprise productivity efficiency, is the basis of agile organizations, for individuals to join the "per capita efficiency" of enterprises, career development is more favorable
.